Sfoglia per Autore
Patterns and trends of idarucizumab use in an Italian region: A probabilistic record-linkage approach in a real-life setting
2020 Lombardi, N; Brilli, V; Crescioli, G; Bettiol, A; Antonazzo, I; Mazzaglia, G; Fumagalli, S; Mannaioni, G; Vannacci, A; Gini, R
Magnitude and time-course of excess mortality during COVID-19 outbreak: population-based empirical evidence from highly impacted provinces in northern Italy
2020 Conti, S; Ferrara, P; Mazzaglia, G; D'Orso, M; Ciampichini, R; Fornari, C; Madotto, F; Magoni, M; Sampietro, G; Silenzi, A; Sileo, C; Zucchi, A; Cesana, G; Manzoli, L; Mantovani, L
Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks and public health considerations
2020 Sultana, J; Mazzaglia, G; Luxi, N; Cancellieri, A; Capuano, A; Ferrajolo, C; de Waure, C; Ferlazzo, G; Trifirò, G
L’approvazione dei farmaci in Europa: dall’analisi sul rischio-beneficio al Risk Management Plan
2019 Mazzaglia, G
Chair sessione: storia della sanita’ pubblica II
2019 Mazzaglia, G; Rippa Bonati, M
Workshop: Indicatori di appropriatezza prescrittiva a sostegno delle politiche sanitarie. Relazione: Valutazione dell’impatto di programmi di minimizzazione del rischio: principi pratici e applicabilità degli indicatori di appropriatezza
2019 Mazzaglia, G
Ruolo della Real World Evidence nello sviluppo pre-marketing di farmaci e dispositivi medici
2019 Mazzaglia, G; Mantovani, L
Risk Management
2019 Manzo, C; Cochino, E; Merchant, L; Mazzaglia, G
Real world evidence during clinical development of drugs
2019 Mazzaglia, G
Accesso alle Terapie con Farmaci Orfani nelle Malattie Rare dello Scheletro
2019 Mazzaglia, G
EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
2019 Cortesi, P; Castaman, G; Trifiro, G; Ferrario, M; Improta, G; Mazzaglia, G; Molinari, A; Mantovani, L
The economic burden of multiple sclerosis development over time: an analysis from the multiple sclerosis centers perspective
2019 Cozzolino, P; Cortesi, P; Patti, F; Capra, R; Berera, G; Mazzaglia, G; Mantovani, L
Risk Minimization
2018 Mazzaglia, G; Straus, S
Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs
2018 Mazzaglia, G; Straus, S; Arlett, P; da Silva, D; Janssen, H; Raine, J; Alteri, E
Risk management process
2018 Cochino, E; Mazzaglia, G; Straus, S
Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases
2017 Ferrajolo, C; Verhamme, K; Trifirò, G; 't Jong, G; Picelli, G; Giaquinto, C; Mazzaglia, G; Stricker, B; Rossi, F; Capuano, A; Sturkenboom, M
Assessing Risk of Osteoporotic Fractures in Primary Care: Development and Validation of the FRA-HS Algorithm
2017 Lapi, F; Bianchini, E; Michieli, R; Pasqua, A; Cricelli, I; Mazzaglia, G; Frediani, B; Prieto-Alhambra, D; Brandi, M; Cricelli, C
Erratum to: Assessing risk of osteoporotic fractures in primary care: development and validation of the FRA-HS algorithm (Calcif Tissue Int, 10.1007/s00223-016-0230-7)
2017 Lapi, F; Bianchini, E; Michieli, R; Pasqua, A; Cricelli, I; Mazzaglia, G; Frediani, B; Prieto-Alhambra, D; Brandi, M; Cricelli, C
Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective
2017 Anton, R; Haas, M; Arlett, P; Weise, M; Balabanov, P; Mazzaglia, G; Prieto, L; Keller-Stanislawski, B; Raine, J
Use of azithromycin and risk of ventricular arrhythmia
2017 Trifirò, G; de Ridder, M; Sultana, J; Oteri, A; Rijnbeek, P; Pecchioli, S; Mazzaglia, G; Bezemer, I; Garbe, E; Schink, T; Poluzzi, E; Frøslev, T; Molokhia, M; Diemberger, I; Sturkenboom, M
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile